Transgenomic Announces Global Availability of CRC RAScan™ Mutation Detection Test for Use in Patients with Metastatic Colorectal Cancer to Help Identify Appropriate Treatment
Transgenomic Reports First Quarter 2013 Financial Results
Reminder: Transgenomic to Hold First Quarter Financial Results Conference Call Today
Transgenomic Signs Collaboration Agreement with Amgen for Development of CE-IVD CRC RAScan™ Mutation Detection Tests for Patients with Metastatic Colorectal Cancer
NOW AVAILABLE CRC RAScan™ Colorectal Cancer Tumor Testing
Transgenomic now offers CRC RAScan™ Colorectal Cancer Tumor Testing in our CLIA-certified laboratory. This is the first dedicated test to more accurately detect the full range of KRAS and NRAS mutations relevant to poor response to EGFR inhibitors. For more information, click here.